| Trial ID: | L3818 |
| Source ID: | NCT01154881
|
| Associated Drug: |
Insulin Degludec
|
| Title: |
A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: insulin degludec
|
| Outcome Measures: |
Primary: Area under the glucose infusion rate curve from 0-24 hours at steady state, 0-24 hours (derived on treatment day 6) | Secondary: Area under the insulin degludec concentration-time curve from 0-24 hours at steady state, 0-24 hours (derived on treatment day 6)
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
49
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2010-06
|
| Completion Date: |
2010-11
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-20
|
| Locations: |
Novo Nordisk Investigational Site, Neuss, 41460, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT01154881
|
